Onivyde

Recurrent Ewing Sarcoma

St. Jude Children's Research HospitalPhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

56 Active assets in the Recurrent Ewing Sarcoma cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Milton S. Hershey Medical Center	Phase 3	BB
Nivolumab Children's National Research Institute	Phase 2	B
Cyclophosphamide Essen Biotech	Phase 2	B
Hycamtin Pfizer	Phase 2	B
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Brenda Cooper, MD	Phase 2	B